Navigation Links
BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
Date:5/14/2012

mpany also recorded $87,215 in other income related to a non-reciprocal, non-monetary receipt of raw materials.

For the first quarter of 2012, the Company reported a net loss of $296,877, or $(0.00) per share, compared with a net loss of $630,122, or $(0.01) per share, for the first quarter of 2011. Loss from operations in the first quarter of 2012 was $179,264, which was 61% lower when compared to the $454,277 loss from operations in the first quarter of 2011.

Outlook for 2012Management expects revenue to continue to increase to approximately $4.1 million in 2012. The Company also expects sales to its contract manufacturing customers to increase significantly with the commencement of deliveries to the previously announced new customer. The Company also expects steady increases in revenue shipments to existing and new direct customers, specifically in the regenerative medicine market segment, as customers continue to move their cell- and tissue-based therapies and products through the clinical trial and regulatory approval processes.

The Company expects slightly lower gross margins as a percentage of revenue in 2012, as a result of increased contract manufacturing, in addition to increased operating expenses associated with selling and product development activity. 

Finally, management believes the Company will achieve positive cash flow from operations in 2012 and that cash generated from customer collections will provide sufficient funds to operate the business.

About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-fre
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
2. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
3. Bowman provides strategies to engage public with climate change solutions
4. Cutting-edge science creating solutions for African agriculture
5. New report reviews US nitrogen pollution impacts and solutions
6. Solutions for a nitrogen-soaked world
7. The path less traveled: Research is driving solutions to improve unpaved roads
8. Veritec and National Identity Solutions (NIS) Sign Significant License Agreement Entering Into a $500 Billion Marketplace
9. New book proposes solutions to social and ecological challenges posed by climate change
10. DST Health Solutions Integrated Care Management Suite Improves Care Quality, Population Management of 31,000+ Member Health Plan
11. Research solutions for sustainability in a rapidly changing world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... of carbon and nitrogen comprise all spheres of ... systems have caused imbalances and perturbations that resulted ... Increased GHGs result in climate changes which influence ... and the atmosphere. Understanding these feedback mechanisms has ... environmental science during the past three decades. , ...
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... Bethesda, MD This FASEB Science Research Conference ... of intestinal lipid digestion and absorption with new ... to understanding the mechanisms of health maintenance and ... resistance and diabetes, dyslipidemia, intestinal failure and gastrointestinal ...
... Conference focuses on recent advances in the methods for ... to promote the discovery and exchange of new methods ... facilitate the application of methods in protein structure analysis ... to support and foster the education of researchers in ...
... from Iowa State University (USA) published a study which ... metals. Now, a team from the University of the ... results throw this discovery into question. This has reaffirmed ... validity in the press. The resistance and elasticity ...
Cached Biology News:Spider silk ties scientists up in knots 2
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... - Researchers are making progress in creating digital transistors ... thought to dramatically limit the material,s use in computers ... of carbon that conducts electricity with little resistance or ... earned a Nobel Prize in physics - it was ...
... was named by FierceBiotech today as one of 2011,s ... promising private biotechnology companies in the industry. This is FierceBiotech,s ... has done a super job of raising the funds and ... combination therapy – toward the market," says Ryan McBride, the ...
... Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 ... today that data from two studies, a Phase II ... compound custirsen (OGX-011/TV-1011), were published in the September issues ... Cancer Research . Custirsen inhibits ...
Cached Biology Technology:Innovation is step toward digital graphene transistors 2FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech 2FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech 3OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 2OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 3OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 4OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 5
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: